Drug Approval | October 29, 2025
FDA approves Alembic's Ticagrelor Tablets, 60 mg
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
cSCC is one of the most common cancers in the U.S. and globally
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Vision loss due to Glaucoma can be prevented if it is detected and treated early
Subscribe To Our Newsletter & Stay Updated
